A recent study found no significant differences in the relative safety profile of biologic agents in patients with moderately to severely active ulcerative colitis (UC).
A team of researchers from Jagiellonian University and the Polish Academy of Sciences, Krakow, Poland, set out to compare the safety profile of biologic drugs in patients with moderately to severely active UC by conducting a systematic review. They searched literature databases to include randomized controlled trials comparing the safety of infliximab, adalimumab, golimumab, and vedolizumab with each other or placebo in patients with UC. The network meta-analysis was performed for an induction phase (6–8 weeks), and maintenance phase (52–54 weeks).
The review included seven randomized controlled trials. For the induction phase, the network meta-analysis was conducted to assess the relative safety profile of adalimumab, golimumab, and vedolizumab; for the maintenance phase, the analysis included infliximab, adalimumab, golimumab, and vedolizumab. According to the Cochrane criteria, the methodological quality of the trials was evaluated as low risk of bias but high risk in the case of attrition bias. Study authors found no significant differences in the rate of adverse events in patients treated with the listed biologics.
Vedolizumab was associated with having the most favorable safety profile in the induction phase, whereas in the maintenance phase, it was infliximab.
Study authors added that more studies are needed to verify the findings, including head-to-head comparisons between the analyzed biologic drugs.
For more information visit onlinelibrary.wiley.com.